Longeveron (LGVN) Stock Price, Quote, News & History | Benzinga

Longeveron Inc (LGVN) Stock Price, Quote, News & History

LGVNNASDAQ

Trade with Public

Trade with Public

$0.6725

-0.17-19.73%

Last update: Aug 25, 12:22 PM

PRO

Why Is It Moving?™:Longeveron shares are trading lower after the company announced a 1-for-10 ...

Stock Split: Longeveron Inc is expected to split Thursday, August 27, 2026 with a ratio of 1:10

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$0.73

Close

-

Volume / Avg.

944.58K / 354.26K

Day Range

$0.65 - $0.73

52 Wk Range

0.48 - 1.23

Market Cap

$21.44M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

5.28%

Days to Cover

7.29

Recent Longeveron Inc News

Stock Market Today: Dow Jones, S&P 500, Nasdaq 1000 Futures Advance as Scott Bessent Expands Sanctions on Iran—NTS, GRRR, REAX, ZM, LGVN in Focus (UPDATED)

U.S. stock futures advanced on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Monday's mixed close.

Rishabh Mishra

Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday

US stock futures mixed as investors focus on earnings from Dick's Sporting Goods, Trade Desk, Intuit, Longeveron, and Zoom Communications.

Avi Kapoor

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.

Henry Khederian

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.

Henry Khederian

Partner Content

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-20.37M

Investing Cash Flow (TTM)

-305.00K

Financing Cash Flow (TTM)

20.42M

Free Cash Flow (TTM)

-20.68M

Capital Expenditure (TTM)

-305.00K

Net Change in Cash (TTM)

-257.00K

Analyst Trends and Forecast

1

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$17.21M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

17.04

PB Ratio (TTM)

2.57

Earnings Yield % (TTM)

-119.36%

Earnings Yield % (FWD)

-87.13%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.33

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$10.08M

Debt to Equity

0.06

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.73

Close

-

Volume / Avg.

944.58K / 354.26K

Day Range

$0.65 - $0.73

52 Wk Range

0.48 - 1.23

Market Cap

$21.44M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

5.28%

Days to Cover

7.29

About

Sector

Health Care

Industry

Biotechnology

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy t...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Longeveron (LGVN) stock?

A

You can purchase shares of Longeveron (NASDAQ:LGVN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Longeveron (LGVN) competitors?

A

Other companies in Longeveron’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Longeveron (LGVN) stock?

A

Longeveron has a consensus price target of $7.00.

Q

What is the current price for Longeveron (LGVN)?

A

The stock price for Longeveron (NASDAQ: LGVN) is $0.6725 last updated August 25, 2026 at 12:22 PM EDT.

Q

Does Longeveron (LGVN) pay a dividend?

A

There are no upcoming dividends for Longeveron.

Q

When is Longeveron (NASDAQ:LGVN) reporting earnings?

A

Longeveron does not have any upcoming earnings scheduled.

Q

Is Longeveron (LGVN) going to split?

A

There is no upcoming split for Longeveron.

Q

What sector and industry does Longeveron (LGVN) operate in?

A

Longeveron is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.